Michel Orsinger has been active at Synthes since 2004, initially as COO and as of 2007 as the company’s Chairman and CEO. Under his leadership, Synthes has sustainably strengthened its position as a globally leading orthopedics and medical technology company. Michel Orsinger has many years of experience in the healthcare industry and an outstanding reputation in the medtech field. The Board of Directors would like to thank Heino von Prondzynski for his valuable contribution to the development of Nobel Biocare, as well as for his successful installation and indoctrination of the company’s new CEO, Richard Laube. Until the 2012 annual general meeting, the previous Vice-Chairman of the Board, Dr. Rolf Watter, will chair the supervisory body on an ad interim basis.
Due to his commitments at Synthes, Michel Orsinger will only become available as of early 2012. With immediate effect, however, he will be attending board meetings as a guest. Consequently, he is at the board’s disposal already today and can work his way into his new task in a timely manner.
“I am looking forward to joining the Board of Nobel Biocare Holding Ltd provided I am elected by the shareholders at the AGM in spring 2012,” said Michel Orsinger. “I know the company since my time as a former Board member and have always been following its development with great interest. Together with Richard Laube, we will further intensify our efforts on innovation, customers and employees.”
"I came to my decision to step down from the Board of Directors after a long period of reflection and only after I had time to work with Richard Laube ensuring that Nobel Biocare is on the right path," said Heino von Prondzynski. "I am pleased that, in Michel Orsinger, a highly qualified professional and outstanding personality has been found to be my successor. He will bring excellent industry expertise and people skills to the Board of Directors. Now that Nobel Biocare is on track, it is my intention to contribute to the unity and strength of the company's senior management. I wish great success to Nobel Biocare and to my successor."
"Michel Orsinger has an outstanding grasp of the medtech and dental industries," said Chairman ad interim, Rolf Watter. "As a guest of the Board he will be able to contribute his vast knowledge and experience with immediate effect. The whole board welcomes him warmly. I would like to thank Heino von Prondzynski for his tremendous dedication and valuable contribution to this development. The Board is also very pleased with the work of CEO Richard Laube to date. The Board of Directors and Executive Committee will refrain from commenting further until the presentation of the half year results on 12 August 2011."
“I regret but understand Heino von Prondzynski’s decision. Since joining the company, I was impressed by how engaged he was in the business, and by how he shared knowledge for the business”, said Richard Laube, CEO of Nobel Biocare. “Michel Orsinger is undoubtedly an eminent expert in this industry. I am confident that our company will greatly benefit from his nomination. I know Michel well and am very much looking forward to working with him again.”